Genetic polymorphisms in Cytochrome P4501B1 and susceptibility to Head and Neck Cancer

Singh, Arvind Pratap; Shah, Parag P.; Mathur, Neeraj; Buters, Jeroen; Pant, M. C.; Parmar, Devendra

doi:10.1016/j.mrfmmm.2007.10.007

Cited by 45 publications

(44 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variant genotype of CYP1B1*2 was associated with several-fold increase in HNC cancer risk among cases of tobacco usage [136]. It also showed variant genotype of CYP1B1*3 to be significantly associated with HNC susceptibility especially among tobacco chewers [136].…”

Section: Head and Neck Cancermentioning

confidence: 85%

See 1 more Smart Citation

Cytochrome P450 in Cancer Susceptibility and Treatment

Mittal

Tulsyan

Kumar

et al. 2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

Section: Head and Neck Cancermentioning

confidence: 85%

“…It also showed variant genotype of CYP1B1*3 to be significantly associated with HNC susceptibility especially among tobacco chewers [136]. Another study reported the presence of variant genotypes of CYP1B1 * 3 at a significantly higher frequency in smokers [137].…”

Section: Head and Neck Cancermentioning

confidence: 99%

Cytochrome P450 in Cancer Susceptibility and Treatment

Mittal

Tulsyan

Kumar

et al. 2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

“…We explored the associations that could exist between genotypes and cell sensitivity with a series of relevant antiproliferative drugs and molecules in the NCI and the JFCR panels, using the same statistical approach as the one we already used in previous studies (8)(9)(10)(11)(12). The R48G and A119S polymorphisms are studied together because their variations are identical.…”

Section: Relationships Between Gene Polymorphisms and Chemosensitivitymentioning

confidence: 99%

“…These polymorphisms may first be of interest in molecular epidemiology. The V432 variant has been associated, for instance, with the risk of lung (7), prostate (8), and head and neck (9) cancers. They may also be of interest in pharmacogenetics, because CYP1B1 is involved in the biotransformations of xenobiotics, including drugs, and its variations may be associated with changes in the cytotoxic activity of anticancer drugs.…”

Section: Introductionmentioning

confidence: 99%

Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models

Laroche-Clary¹,

Morvan²,

Yamori³

et al. 2010

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Cytochrome P450 1B1 (CYP1B1) is found in tumor tissue and is suspected to play a role in oncogenesis and drug resistance. CYP1B1 gene polymorphisms have been associated with the risk of developing lung and other cancers. They may be associated with tumor response to anticancer drugs. We have determined 4 frequent nonsynonymous gene polymorphisms of CYP1B1 in the human tumor cell lines panels of the National Cancer Institute (NCI) and the Japanese Foundation for Cancer Research (JFCR): rs10012 (R48G), rs1056827 (A119S), rs1056836 (L432V), and rs1800440 (N453S). Numerous anticancer drugs have been tested against these panels that offer the opportunity to detect associations between gene polymorphisms and drug sensitivity. CYP1B1 single nucleotide polymorphisms were in marked linkage disequilibrium. The L432V allelic variants were significantly associated with reduced sensitivity to DNA-interacting anticancer agents, alkylators, camptothecins, topoisomerase II inhibitors, and some antimetabolites. For instance, in the NCI panel, cell lines homozygous for the V432 allele were globally 2-fold resistant to alkylating agents (P ¼ 5 Â 10 À10 ) and 4.5-fold to camptothecins (P ¼ 6.6 Â 10 À9 ) than cell lines homozygous for the L432 allele. Similar features were exhibited by the JFCR panel. Cell lines homozygous for the V432 allele were globally less sensitive to DNA-interfering drugs than cell lines having at least 1 common allele. There was no significant association between mRNA expression of CYP1B1 and CYP1B1 genotype, and no significant association between CYP1B1 mRNA expression and drug cytotoxicity. These observations open the way to clinical studies exploring the role of CYP1B1 gene polymorphisms for predicting tumor sensitivity to chemotherapy. Mol Cancer Ther; 9(12); 3315-21. Ó2010 AACR.

show abstract

“…Tobacco smoking and alcohol abuse are strong risk factors for developing HNSCC, and synergistic effects for these risk factors have been demonstrated [Hecht and Hoffmann, 1988;Hashibe et al, 2007;Werbrouck et al, 2008]. Likewise, polymorphisms in cytochrome P450 1B1 (CYP1B1), CYP2C19, and glutathione S-transferases (GSTs), involved in the metabolic activation and detoxification of carcinogens, are known to increase the risk of HNSCC [Singh et al, 2008a[Singh et al, , 2008bYadav et al, 2008]. CYP2E1 is a major component of the microsomal ethanol oxidation system.…”

Section: Introductionmentioning

confidence: 99%

Cytochrome P450 2E1 and head and neck cancer: Interaction with genetic and environmental risk factors

Ruwali

Khan

Shah

et al. 2009

Environ and Mol Mutagen

Self Cite

View full text Add to dashboard Cite

The present case-control study investigates the association of polymorphisms in cytochrome P450 2E1 (CYP2E1), involved in the metabolism of tobacco carcinogens and alcohol, with Head and Neck Squamous Cell Carcinoma (HNSCC). In addition, the interaction of CYP2E1 (CYP2E1*5B and CYP2E1*6) with other genetic factors (null genotype of glutathione-S-Transferase M1, GSTM1, X-Ray Repair Cross Complementing Group I, XRCC1 (Arg194Trp), and environmental risk factors such as alcohol and tobacco in modifying HNSCC risk were investigated. Genotypes were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a total of 350 male cases of HNSCC and an equal number of healthy male controls. Statistical analysis showed a significant increase in HNSCC risk in cases with variant genotypes of CYP2E1*5B (RsaI) (O.R. 3.44; 95% C.I. 1.45-8.14) and CYP2E1*6 (DraI) (O.R. 1.76; 95% C.I. 1.28-2.41). Haplotype analysis revealed that haplotype T-A was associated with a greater than 10-fold increase in risk for HNSCC. Our data also revealed a several fold increase in HNSCC risk in cases carrying a combination of variant genotypes of CYP2E1 with the null genotype of GSTM1 or XRCC1 variant genotypes. Alcohol or tobacco use (both smoking and chewing) were also found to interact with variant genotypes of CYP2E1 in significantly enhancing HNSCC risk. This increase in risk associated with an interaction of CYP2E1 genotypes with GSTM1 or XRCC1 or with tobacco and alcohol use demonstrates the importance of gene-gene and gene-environment interactions in the development of HNSCC.

show abstract

Genetic polymorphisms in Cytochrome P4501B1 and susceptibility to Head and Neck Cancer

Cited by 45 publications

References 27 publications

Cytochrome P450 in Cancer Susceptibility and Treatment

Cytochrome P450 in Cancer Susceptibility and Treatment

Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models

Cytochrome P450 2E1 and head and neck cancer: Interaction with genetic and environmental risk factors

Contact Info

Product

Resources

About